Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Advertisement

Currently submitted to: JMIR Dermatology

Date Submitted: Dec 23, 2019
Open Peer Review Period: Dec 23, 2019 - Feb 23, 2020
(currently open for review and needs more reviewers - can you help?)

Evaluation of the Level of Evidence Supporting the Recommendations Constituting the American Academy of Dermatology Clinical Practice Guidelines: Cross-Sectional Analysis

  • Courtney Cook; 
  • Ryan Ottwell; 
  • Taylor Rogers; 
  • Jake Checketts; 
  • Sanjeev Musuvathy; 
  • Matt Vassar; 

ABSTRACT

Background:

Clinical practice guidelines are evidence based recommendations used by dermatologists to improve patient care. These guidelines provide the physician with an assessment of the benefits and harms of a treatment and its alternatives. Therefore, it is essential that the clinical practice guidelines be based on the strongest available evidence. Numerous studies in a variety of different fields of medicine have demonstrated that recommendations supported by weak evidence are a common theme in clinical practice guidelines. A clinical guideline based solely on weak evidence has the capability to reduce the quality of care provided by dermatologists.

Objective:

Our primary objective is to evaluate the levels of evidence supporting the recommendations constituting the American Academy of Dermatology clinical practice guidelines.

Methods:

Using a cross-sectional study design, investigators SM and RO located all current clinical practice guidelines from the American Academy of Dermatology website on June 10, 2017 and December 11, 2019. Each recommendation and its corresponding evidence rating were extracted in a duplicate and blinded fashion. A consensus meeting was planned a priori to resolve disagreements in extractions or stratifications.

Results:

Six clinical guidelines and their subsections were screened and 899 recommendations were identified. Our final data included 841 recommendations, as 58 of the recommendations contained no level of evidence and were excluded from calculations. The majority of the recommendations were supported by a moderate level of evidence and therefore received a B rating (346/841, 41.1%). Roughly one-third of the recommendations were supported by a strong level of evidence and were given an A rating (307/841, 36.5%). The clinical practice guideline with the highest overall strength of evidence was regarding the treatment of acne, which had 17 of 35 (48.6%) recommendations supported by strong evidence and only two (2/35, 5.7%) supported by weak evidence. The clinical practice guideline with the least amount of recommendations supported by strong evidence was melanoma (13/63, 20.6%).

Conclusions:

Clinical practice guidelines that lack strong supporting evidence could negatively affect patient care, and dermatologists should be mindful that not all recommendations are supported by the strongest level of evidence. Increased quantity and quality of research needs to be performed in the field of dermatology to improve the evidence supporting the American Academy of Dermatology clinical practice guidelines.


 Citation

Please cite as:

Cook C, Ottwell R, Rogers T, Checketts J, Musuvathy S, Vassar M

Evaluation of the Level of Evidence Supporting the Recommendations Constituting the American Academy of Dermatology Clinical Practice Guidelines: Cross-Sectional Analysis

JMIR Preprints. 23/12/2019:17370

DOI: 10.2196/preprints.17370

URL: https://preprints.jmir.org/preprint/17370


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.